Lncbio
Public · 1 known investors
A biotechnology company that develops creative biotech solutions to improve human health and well-being.
Also known as L&C BIO · L&C Bio Co., Ltd. · LNC Bio
Investors · 1
Company profile
researched Aug 2026L&C Bio Co., Ltd. (lncbio.co.kr) is a South Korea-based company principally engaged in the medical business. Its core activity is the manufacture and sale of tissue engineering therapeutic materials, including human tissue grafts and human tissue-based medical devices. The company also manufactures and supplies cosmeceuticals, and is active in pharmaceuticals, functional cosmetics, health functional foods and imaging devices.
The company is headquartered in Seongnam-si, Gyeonggi-do, in the Suntech City building at 474 Dunchon-daero, Jungwon-gu, where it occupies multiple units. It is accredited as a tissue bank by the Association for Advancing Tissue and Biologics (accreditation number 00363, expiring 8 August 2027) for distribution, donor eligibility determination, processing and storage of musculoskeletal and skin tissue. As of the most recent disclosure it employed 172 people.
Business model
The company generates revenue from manufacturing and selling tissue engineering therapeutic materials (human tissue grafts and human tissue-based medical devices) and cosmeceuticals, alongside activity in pharmaceuticals, functional cosmetics, health functional foods and imaging devices. Reported sales are grouped under a single "Medical Products" activity segment.
Product sales of medical and tissue-derived products; medical product revenue was KRW 45.68B in 2021, KRW 52.57B in 2022, KRW 68.87B in 2023, KRW 72.09B in 2024 and KRW 85.48B in 2025.
Traction
Medical product sales grew from KRW 45.68B in 2021 to KRW 85.48B in 2025, with overseas sales rising from KRW 3.9B in 2022 to KRW 5.98B in 2025. The company holds tissue bank accreditation from the Association for Advancing Tissue and Biologics for musculoskeletal and skin tissue distribution, donor eligibility determination, processing and storage.
Latest developments
In December, the company announced it expected to receive and then confirmed receipt of approximately KRW 15.0 billion in funding from Humedix Co., Ltd. Jae-Ho Lee was appointed Chief Executive Officer effective 28 February 2025, serving alongside CEO Hwan-Chul Lee, and Yong-Wan Jo joined the board on 30 March 2025.
▸Full profile — market position, technology, geography, history
Market position
Classified in the medical devices and implants / medical equipment, supplies and distribution sector, with market data listing peers such as Stryker, Smith & Nephew, Glaukos, Imeik Technology Development, Double Medical Technology, Insight Lifetech, Inspire Medical Systems and Shanghai MicroPort Endovascular. Market capitalization was reported at about $1.04 billion, with three analysts covering the stock and an average target price of KRW 95,000 against a last close of KRW 52,900.
Technology
Tissue engineering therapeutic materials derived from human tissue, including human tissue grafts and human tissue-based medical devices, supported by accredited processing, storage, distribution and donor eligibility determination capabilities for musculoskeletal and skin tissue.
Geography
Headquartered in Seongnam-si, Gyeonggi-do, South Korea. Sales are predominantly domestic: in 2025, KRW 79.5B of sales came from South Korea versus KRW 5.98B from overseas markets.
History
Shareholders include founder-level holder Hwan-Chul Lee (23.45%), Nau IB Capital Co. Ltd. (8.215%), VIP Research & Management Inc. (5.365%), treasury shares (0.8611%) and an employee stock ownership association (0.5335%). The board comprises Hwan-Chul Lee, Jae-Ho Lee and Tae-Seon Jeon (both since 28 March 2023) and Yong-Wan Jo (since 30 March 2025).
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsAccredited by the Association for Advancing Tissue and Biologics (accreditation number 00363, expiring 2027-08-08) for distribution, donor eligibility determination, processing and storage of musculoskeletal and skin tissue.
The company announced it has received KRW 14.9999136 billion in funding from Humedix Co., Ltd.
The company announced it expects to receive KRW 14.9999808 billion in funding from Humedix Co., Ltd.
Yong-Wan Jo (age 50) became a director/board member.
Jae-Ho Lee (age 51) took office as Chief Executive Officer, serving alongside CEO Hwan-Chul Lee.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Lncbio do?
- Korean listed medical company making human tissue grafts, tissue-based medical devices and cosmeceuticals.
- Who are Lncbio's investors?
- Lncbio's investors include Kiwoom Investment.